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Introduction
The final round of the UEFA European Football Championship is a 
tournament for the top national teams in European men’s football and 
is held every four years. The 2012 tournament was contested by 16 
teams, which reached the final round via a series of qualification 
matches held over the preceding two years. That tournament was the 
14th to be staged by UEFA and the first to be staged in the neighbour-
ing countries of Poland and Ukraine. The tournament began in War-
saw on 8 June 2012 and ended with the final in Kiev on 1 July 2012. 
Teams listed in Table 1 qualified for the final tournament, and a total 
of 367 players were registered to take part (23 from each country, 
with the exception of one team that registered only 22 players)
UEFA has many years of experience with the planning of in- and 
out-of-competition doping controls in elite football and operates an 
annual anti-doping programme for all of its national and club com-
petitions. The programme uses an experienced team of doping con-
trol officers (DCOs), established sample transport procedures and   
a network of World Anti-Doping Agency (WADA)-accredited labora-
tories across Europe to ensure maximum effectiveness. As the final 
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round of the UEFA European Football Championship is one of the 
world’s top sporting events and UEFA’s flagship tournament at na-
tional level, it is imperative that an effective anti-doping programme 
is in place to deter and detect doping, seeking to ensure that all 
results are achieved fairly and without the use of prohibited perfor-
mance-enhancing substances. Consequently, the aim for UEFA at 
UEFA EURO 2012 was to adapt its established anti-doping pro-
cesses to ensure an effectively planned and executed anti-doping 
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TABLE  1.  TEAMS  QUALIFIED  FOR  THE  FINAL  ROUND  OF 
THE UEFA EUROPEAN FOOTBALL CHAMPIONSHIP
Group A Group B Group C Group D
Poland Netherlands   Spain France
Greece  Denmark  Italy  England 
Russia Germany Republic of 
Ireland Ukraine  
Czech 
Republic Portugal  Croatia  Sweden    
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programme at the tournament. This was a significant challenge, with 
the tournament taking place in two host countries, each with four 
host cities spread over a wide geographical area, and only one WADA 
accredited laboratory in the two countries at which to analyse sam-
ples.
The tournament’s anti-doping programme involved both pre-
tournament out-of-competition testing of competing squads at their 
preparatory training camps and a full programme of in-competition 
testing at all matches in the tournament. Testing was supplemented 
by a pre-tournament education and information programme for par-
ticipating teams and players. 
Applicable rules
The UEFA Anti-Doping Regulations comply with those of FIFA, as 
well as the standards established by the WADA. These regulations 
were in force at the tournament. For the purposes of WADA’s Pro-
hibited List, UEFA regulations specify that the tournament’s in-
competition period commences 24 hours before the first match of 
the tournament and ends 24 hours after the final match. This meant 
that all pre-tournament samples were analysed on the basis of an 
out-of-competition analytical menu and all tournament samples 
(including those collected between matches) were analysed on the 
basis of an in-competition analytical menu. Anti-doping rule viola-
tions (ADRVs) and associated penalties were as specified in FIFA’s 
regulations and the World Anti-Doping Code (WADC) [1].
Doping control officers 
Selection
The collection of samples for the pre-tournament and tournament 
programmes was conducted solely by UEFA DCOs and blood col-
lection officers (BCOs). DCOs are only qualified to collect urine 
samples, while BCOs are qualified to collect both urine and blood 
samples . UEFA manages a team of approximately 40 DCOs across 
Europe, all of whom are medical doctors with many years of experi-
ence in conducting doping controls for UEFA, national anti-doping 
organisations (NADOs) and other international sports federations.  
DCOs were selected to collect samples for the tournament and 
pre-tournament programmes on the basis of criteria such as doping 
control experience and aptitude, proximity to the test venue, nation-
ality (to limit suggestions of bias), recent blood collection experience, 
and languages spoken. For the pre-tournament programme, nine 
BCOs and 12 DCOs were used to collect samples, with some un-
dertaking multiple assignments on consecutive days. Doping controls 
were normally conducted during teams’ scheduled training sessions 
(with samples collected in places as diverse as Dublin, Moscow and 
Visby), and the DCOs/BCOs then delivered the samples to the WADA 
accredited laboratory in Warsaw by plane. For the in-competition 
programme, a team comprising six DCOs and six BCOs was se-
lected, with officers working in the same designated pairs at all of 
their appointed matches. The DCOs/BCOs were based permanently 
in Warsaw, close to the tournament laboratory, and travelled by plane 
to each game on the morning of the match, before returning on the 
first flight the following morning.  
Training and performance monitoring
All UEFA DCOs are trained to collect urine samples in accordance 
with the WADA International Standard for Testing (IST) [2] as part 
of their role in UEFA’s annual anti-doping programme, so no new 
procedural training was required for the tournament programme. For 
BCOs, specific instructions on procedures and the use of blood 
sampling equipment were provided in advance of their first assign-
ment in connection with the tournament. In addition, all DCOs were 
briefed collectively on arrival in Warsaw for the in-competition pro-
gramme by means of a preparatory workshop covering documenta-
tion, equipment, player selection and logistical procedures. During 
the tournament, DCOs were required to attend a debriefing session 
after each doping control to review procedures and provide feedback 
in the event that improvements could be made for the next match. 
During the tournament, DCOs’ performance was monitored by a 
team of observers consisting of members of UEFA’s anti-doping unit, 
the UEFA Anti-Doping Panel and the UEFA Medical Committee. In 
addition, the Chairman of the UEFA Anti-Doping Panel was present 
for the full duration of the tournament to review the DCOs’ activities.
 
Equipment and logistics
Transport of samples
The large distances between the host cities (Warsaw, Wroclaw, 
Gdansk and Poznan in Poland, and Kyiv, Donetsk, Kharkiv and Lviv 
in Ukraine) made ground transport of samples unfeasible, particu-
larly considering the time restrictions on the safe transport of blood 
samples and the tight time frames between matches for the report-
ing of sample results. Consequently, all samples were transported 
by plane (i) on the day the sample was collected for pre-tournament 
out-of-competition samples or (ii) on the morning after the match 
(on the first available flight) for in-competition samples. This required 
the careful planning of flights for DCOs, as well as the prior agree-
ment of domestic and international airlines and customs authorities 
to ensure the safe and unimpeded transport of samples as cabin 
baggage in the custody of DCOs. During the tournament, this process 
was facilitated by the provision of advance notification of DCOs’ 
travel plans to the local organising committee (LOC) airport co-or-
dinators based in each host city airport, as well as by written letters 
of agreement from airlines. The pre-notification process was accept-
able in terms of disclosure risk, as all tournament matches were to 
involve testing, so the prior notification of dates did not reveal any 
aspect of the test distribution plan. Other testing conducted during 
the tournament was not disclosed to airport or customs staff until 
samples had been collected.
No problems were experienced with the cross-border transport 
of samples by DCOs, either by road or by plane, despite some 
delays to scheduled flights’ departure times during the competition 
period.  
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Sample collection kit 
Collecting and transporting samples, particularly blood samples, 
always presents a unique challenge, with the need to ensure that 
the integrity of samples is maintained during the journey from the 
collection site to the laboratory. This is particularly difficult where 
travel over longer distances is required. The kit used has to be reli-
able, trusted by the players and teams, and – perhaps most impor-
tantly – easy for DCOs and BCOs to use, store and transport.  
All sample collection kits and associated equipment used in 
connection with the tournament were supplied by the company 
Berlinger from Switzerland, which also supplies kits for UEFA’s 
annual anti-doping programme. Berlinger is one of the leading sup-
pliers of equipment for anti-doping programmes in international 
sport.
Urine and blood samples were collected using standard Berlinger 
Bereg kits. Blood samples were taken with a butterfly needle. Four 
separate tubes were needed for whole blood and serum in order to 
store all of the samples (an “A” and “B” sample for each). As blood 
and serum samples need to be analysed shortly after collection, 
and must be kept at a very stable temperature (between 4 and 
12°C), cooling equipment was required to maintain this temperature 
for at least 48 hours. The Nanocool box was used for this purpose 
for all tournament and pre-tournament blood and serum samples, 
with a Q Tag device to monitor the temperature during transit. 
Nanocool boxes were prepared by BCOs for out-of-competition test-
ing and by the Warsaw laboratory for in-competition testing. All 
blood samples were securely refrigerated in the doping control sta-
tion until the collection of samples had been completed, at which 
point the Nanocool box was activated by the BCO.
Management of Therapeutic Use Exemptions (TUEs)
Management of TUEs followed UEFA’s usual procedure, which com-
plies with WADA’s International Standard for TUEs [3]. All TUE 
applications for players had to be submitted to UEFA 21 days before 
the start of the tournament (with the exception of emergency cases, 
which could be reviewed at shorter notice if they occurred just prior 
to the start of the tournament). 
Between 1 May 2012 and 2 July 2012, UEFA granted one TUE 
for glucocorticosteroids. This was the only TUE applied for in con-
nection with the tournament.  
Out-of-competition testing programme
The test distribution plan for the pre-tournament programme was 
complicated by a combination of (i) the unique legal arrangements 
in European football, whereby UEFA has jurisdiction over players 
only when they are competing in its competitions, and (ii) the short 
period of time that teams had to prepare for the tournament after 
the completion of their domestic club seasons. In effect, a three 
week window was available in which to conduct out-of-competition 
doping controls. This was the time between the point at which se-
lected players met for pre-tournament training for the first time and 
the point at which teams left their training camps for the host coun-
tries. The start date for training camps is usually determined by the 
date that the domestic and European club season ends and will also 
depend on the countries in which the majority of the team’s players 
play their club football (which is often not their national league). The 
first participating team to meet for a pre tournament training camp 
did so on 9 May 2012, while the last team met up for the first time 
on 24 May 2012.
Team whereabouts 
To enable UEFA to plan its programme, teams were required to 
supply their overall pre tournament schedule approximately one 
month in advance of the tournament (by 27 April 2012). As of   
1 May 2012 (or the week of the first training camp if it was later), 
all 16 participating teams had to submit detailed whereabouts in-
formation to UEFA via weekly reports/schedules for the following 
week, which had to be submitted every Friday before 12.00 CET, in 
accordance with the standard procedure applied by UEFA in the 
UEFA Champions League. Whereabouts submissions consisted of 
training camps/sessions, friendly matches, the address of the train-
ing ground or match venue, and the address of the hotels/training 
camps where the team was staying.
Whereabouts violations were handled in accordance with the 
UEFA Anti-Doping Regulations, with teams subject to team non-
compliances for failing to submit accurate information (or provide 
updates) about the location of the team or individual players, and 
with players subject to individual non-compliances for failing to 
update UEFA in advance regarding their absence from collective 
team activities, where that resulted in them missing doping controls.   
Sample collection and analysis
Following a recommendation by the UEFA Anti-Doping Expert Panel, 
the UEFA Executive Committee decided that both blood and urine 
samples should be collected at each doping control, both prior to and 
during the tournament. This was a continuation of the policy ad-
opted at the 2008 tournament, which had been the first time that 
both blood and urine analysis had been implemented at a major 
international sports event. In total, 284 players were tested in con-
nection with the 2012 tournament on the basis of an analytical menu 
that was devised by experts from leading WADA accredited labora-
tories in Europe and approved by the UEFA Anti-Doping Expert 
Panel. The menu included partial screening for out-of-competition 
samples and, in addition, testing for artificial haemoglobin, blood 
transfusion (whole blood), blood parameters (whole blood), hGH (se-
rum), EPO (urine), CERA (serum), [4,5,6,7] SARMS (urine – as part 
of the partial OOC screen) and plasticisers (urine), as well as IRMS 
analysis (which can identify endogenous and exogenous intake of 
anabolic steroids, providing a complete individual steroid profile).
All out-of-competition doping controls conducted pre-tournament 
involved ten players from the team undergoing blood, urine and 
serum tests with no notice at the team’s pre-tournament training   
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camp. All participating teams were visited at least once prior to the 
start of the tournament, and a total of 160 tests were administered 
(Table 2). Teams were responsible for organising a suitable doping 
control station (DCS), either at the training venue or at the hotel 
where the team was staying.
All out-of-competition samples were analysed at the laboratory 
of the Department of Anti-Doping Research at the Institute of Sport 
in Warsaw to ensure consistency of analysis and results across 
samples. All procedures were supervised by experienced experts from 
other WADA accredited laboratories during the pre- and in-compe-
tition phase. All samples were received by the laboratory within 24 
hours of collection and were analysed within 48 hours of receipt 
(with the exception of IRMS analysis, which was conducted within 
96 hours) (Table 3). All samples collected in the out-of-competition 
programme came back negative.  
In-competition testing programme
Doping controls were conducted after every match at the tourna-
ment, with two players from each team drawn to undergo testing, 
plus two reserves. Reserves were available to be tested in the event 
that a selected player sustained an injury that rendered him inca-
pable of completing the test (which did not occur at any tournament 
match). Any of the 23 squad players could be drawn for testing, 
regardless of whether they actually participated in the match.  
32 doping control chaperones (four per stadium) were appointed 
to assist with the in-competition programme from the pool of tourna-
ment volunteers. Where possible, chaperones came from the na-
tional anti-doping organisations of the host countries. In Poland, five 
chaperones were experienced anti-doping officers from Komisja do 
Zwalczania Dopingu w Sporcie (Polish Commission Against Doping 
in Sport), and all other chaperones were selected from the volunteer 
pool.
All chaperones were trained by UEFA’s anti-doping unit in advance 
of the tournament via a specially designed distance learning pro-
gramme. In addition, a support service was made available within 
the anti-doping unit to ensure that any questions regarding the role 
could be answered by experienced staff. Finally, all chaperones were 
given a full pre-match briefing by a DCO before their first match at 
the tournament. 
The in-competition programme commenced with the first tourna-
ment match on 8 June 2012 between Poland and Greece, and 
ended on 1 July 2012 with the final between Spain and Italy.
Partial screen for OOC samples 
(urine) Ten players per team
EPO (urine) Five players per team
IRMS (urine)
Two players per team, and only 
if required by WADA technical 
documents
SARMS (urine) Ten players per team
CERA (serum) Ten players per team
HGH (serum) Ten players per team
Blood parameters (whole blood) Ten players per team
Blood transfusion Two players per team
Plasticisers (useful when 
combined with blood 
parameters)
Ten players per team 
TABLE 2. OUT-OF-COMPETITION ANTI-DOPING LABORATORY’S 
ANALYTICAL MENU AND DISTRIBUTION
TABLE 3. OVERVIEW OF THE DELIVERY CONDITIONS OF THE OUT-OF-COMPETITION SAMPLES (20 X BLOOD AND 10 X URINE 
SAMPLES PER MISSION) TO THE WARSAW LABORATORY INCLUDING TEMPERATURE INFORMATION (Q-TAG SYSTEM)
Collection date End of collection* Delivery date Travel time** Q-Tag nformation Max. temperature (°C)
18 May 2012 14.25 19 May 2012 22 h 20 min OK/OK
21 May 2012 14.20 22 May 2012 18 h 20 min Not activated/ Not activated
21 May 2012 16.01 22 May 2012 17 h 44 min OK/OK
23 May 2012 19.30 24 May 2012 15 h 45 min OK/Alarm –– / 18.4
23 May 2012 14.40 24 May 2012 21 h 45 min OK/OK
23 May 2012 20.20 24 May 2012 16 h 35 min OK/Alarm –– / 24.6
24 May 2012 14.40 25 May 2012 18 h 45 min OK/Broken
25 May 2012 14.40 25 May 2012 8 h 35 min Alarm/OK > 16 / ––
25 May 2012 16.30 26 May 2012 21 h 40 min OK/Alarm –– / 19.4
26 May 2012 13.00 26 May 2012 10 h 40 min OK
27 May 2012 14.46 27 May 2012 8 h 26 min OK/OK
28 May 2012 14.10 28 May 2012 7 h 20 min OK
28 May 2012 14.15 29 May 2012 22 h 15 min OK/OK
29 May 2012 20.40 30 May 2012 15 h 15 min Alarm/OK 22.5 / ––
31 May 2012 21.10 1 June 2012 18 h 30 min Alarm 23.2
2 June 2012 20.45 3 June 2012 19 h 40 min OK/OK
Note: * download time of the last sample of urine/blood prior to transport to laboratory, ** time from the end of collection to delivery to the laboratory  
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Doping control stations (DCSs) at tournament stadiums were of 
extremely high quality, as most of the stadiums were newly built, 
with specific consideration given in the planning stage to the design 
and location of the facility. All DCSs used at the tournament were 
inspected by members of the UEFA Medical Committee and anti-
doping unit staff at site visits conducted in 2011 and 2012.
In-competition samples were analysed for the full WADA analytical 
menu plus additional screening for EPO, HGH, blood transfusion and 
SARMS, with IRMS analysis conducted as required [8,9] (Table 4). 
All samples were received by the laboratory within 24 hours of col-
lection and were analysed within 24 hours of receipt (with the ex-
ception of EPO and IRMS analysis, which was conducted within   
48 hours). All results were reported before the team’s next match. 
All samples were analysed by the WADA-accredited laboratory in 
Warsaw under the supervision of experienced experts from other 
WADA accredited laboratories.
the Lausanne laboratory. Training was also offered by manufactur-
ers providing new analytical equipment.
Pre-analytics
Table 6 summarises the pH and specific gravity of the urine sam-
ples (A samples) collected during in-competition and out-of-com-
petition testing.
Urine testing
Out-of-competition urine samples were tested for the following 
prohibited substances included on WADA’s 2012 Prohibited 
List [10]:
S1: Anabolic agents
1. Anabolic androgenic steroids (AASs)
2. Other anabolic agents
S2: Peptide hormones, growth factors and related substances
1. Erythropoiesis-stimulating agents
2. Chorionic gonadotropin (CG) and luteinising hormone (LH) 
5.  Growth hormone
S3: Beta-2 agonists
S4: Hormone and metabolic modulators
1. Aromatase inhibitors
2. Selective oestrogen receptor modulators (SERMs)
3. Other anti-oestrogenic substances
5. Metabolic modulators: peroxisome proliferator activated re-
ceptor δ (PPAR δ) agonists (e.g. GW 1516)
S5: Diuretics and other masking agents
M1. Enhancement of oxygen transfer
1. Blood doping
2. Artificially enhancing the uptake, transport or delivery of 
oxygen, including efaproxiral (RSR13)
In-competition urine samples were also screened for:
S6: Stimulants
S7: Narcotics
S8: Cannabinoids
S9: Glucocorticosteroids
In the pre-tournament testing programme, samples from two of 
the ten players tested in each team were analysed for synthetic tes-
tosterone or testosterone precursors using gas chromatography com-
bustion isotope ratio mass spectrometry (GC/C/IRMS), with other 
samples analysed in this way if required by WADA technical docu-
ments. At the in-competition stage, analysis using GC/C/IRMS was 
performed only when required by WADA technical documents [8,9].
The distribution of testosterone to epitestosterone (T/E) ratios in 
out-of-competition and in competition samples is shown in Figure 1 
and Figure 2.
All samples with a T/E ratio in excess of 4.0 were analysed using 
IRMS in accordance with the requirements laid down in the WADA 
TABLE  4.  IN-COMPETITION  ANTI-DOPING  LABORATORY’S 
ANALYTICAL MENU AND DISTRIBUTION (31 MATCHES)
Full screen for IC samples  Four samples per match
EPO (urine) Four samples per match as of 
quarter-finals
IRMS (urine) If requested by WADA technical 
documents
SARMS (urine) Four samples per match
HGH (serum) Four samples per match
Blood transfusion (whole 
blood)
Four samples per match as of semi-
finals
All 124 players’ blood and urine samples collected in the in-
competition programme were returned as negative. On three occa-
sions, blood could not be successfully collected from a player (with 
two of these incidents involving the same player). Following the 
conclusion of the tournament, all samples were placed in storage (at 
-20°C) and will be retained for re-analysis by UEFA as required.
Transport to the laboratory
Overview of the delivery conditions of IC samples (standard four 
blood and four urine samples per match) to the Warsaw laboratory 
is presented in Table 5.
Results and discussion
Sample analysis
In accordance with WADA’s quality control requirements, tourna-
ment samples were analysed to the highest possible standards. 
Analysts working in the laboratory in Warsaw were trained prior to 
the tournament in the Lausanne and Seibersdorf laboratories, and 
pre-tournament training was conducted in Warsaw by experts from   
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International Standard for Laboratories [11,12,13]. No indication of 
the use of synthetic testosterone or testosterone precursors was iden-
tified. The Warsaw laboratory also sent all steroid profile parameters 
to UEFA in order to compare those results with the results of previous 
analysis.
The presence of recombinant erythropoietin was tested for using 
ultrafiltration, isoelectric focusing (IEF), double blotting and chemi-
luminescence detection [14,15,16,17]. For suspicious profiles, an 
SDS PAGE test was conducted straight after screening [18]. All results 
were negative. The percentage of samples with suspicious profiles 
was approximately 19% for out-of-competition samples and ap-
proximately 6% for in-competition samples. 
Each of the OOC samples was analysed for the presence of plas-
ticiser metabolites [19]. Although the presence of elevated levels of 
these indicators is not unambiguous proof of the use of blood trans-
fusion, this represents important additional evidence alongside the 
blood passport programme [20]. No suspicious results were detected.
Blood parameter distribution
Blood parameters were only analysed in the out-of-competition pro-
gramme. A full blood count was obtained for all blood samples, and 
the stimulation index (OFF score) and abnormal blood profile 
score (ABPS) were calculated [21,22,23]. Blood parameters were 
Collection date End of collection* Delivery date Travel time** Q-Tag nformation Max. temperature (°C)
8 June 2012 21.25 8 June 2012 25 min OK
8 June 2012 23.30 9 June 2012 7 h 40 min OK
9 June 2012 22.00 10 June 2012 17 h 15 min OK
10 June 2012 21.25 11 June 2012 9 h 55 min OK
10 June 2012 00.35 10 June 2012 15 h 45 min OK
11 June 2012 23.18 12 June 2012 19 h 7 min OK
11 June 2012 01.10 11 June 2012 6 h 30 min OK
12 June 2012 21.00 13 June 2012 10 h 55 min OK
12 June 2012 01.40 12 June 2012 9 h 20 min Alarm > 12
13 June 2012 21.45 14 June 2012 15 h 10 min OK
13 June 2012 00.15 13 June 2012 35 min OK
14 June 2012 21.48 15 June 2012 8 h 52 min OK
14 June 2012 00.45 14 June 2012 15 h 10 min OK
15 June 2012 23.25 16 June 2012 16 h 45 min OK
15 June 2012 01.10 15 June 2012 10 h 30 min OK
16 June 2012 01.20 16 June 2012 8 h 25 min OK
17 June 2012 00.15 17 June 2012 35 min OK
17 June 2012 00.25 17 June 2012 7 h 5 min OK
18 June 2012 00.40 18 June 2012 15 h 20 min OK
18 June 2012 00.30 18 June 2012 15 h 40 min OK
19 June 2012 02.00 19 June 2012 5 h 8 min OK
19 June 2012 00.28 19 June 2012 6 h 52 min OK
20 June 2012 00.10 20 June 2012 10 h 30 min OK
20 June 2012 01.30 20 June 2012 15 h 50 min OK
22 June 2012 00.16 22 June 2012 34 min OK
22 June 2012 23.45 23 June 2012 7 h 15 min OK
24 June 2012 01.55 24 June 2012 14 h 40 min OK
25 June 2012 02.34 25 June 2012 7 h 1 min OK
28 June 2012 02.15 28 June 2012 16 h 25 min OK
29 June 2012 00.11 29 June 2012 24 min OK
2 July 2012 01.54 2 July 2012 7 h 36 min OK
Note: * download time of the last sample of urine/blood prior to transport to laboratory, ** time from the end of collection to delivery to the laboratory
TABLE 5. OVERVIEW OF THE DELIVERY CONDITIONS OF IC SAMPLES (STANDARD FOUR BLOOD AND FOUR URINE SAMPLES PER 
MATCH) TO THE WARSAW LABORATORY, INCLUDING TEMPERATURE INFORMATION (Q-TAG SYSTEM)
pH Specific gravity
OOC 
samples
IC 
samples
OOC 
samples
IC 
samples
Total samples 160 132 160 132
Mean 6.08 5.87 1.018 1.014
Median 6.00 5.69 1.017 1.011
Min. 5.08 5.07 1.003 1.002
Max. 7.72 7.75 1.035 1.036
SD* 0.55 0.53 0.008 0.009
CV** 9% 9% 0.8% 0.9%
TABLE 6. OUT-OF-COMPETITION ANTI-DOPING LABORATORY’S 
ANALYTICAL MENU AND DISTRIBUTION
Note: *  standard deviation, ** coefficient of variation  
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not analysed in-competition, as in competition blood test results were 
shown at UEFA EURO 2008 [24] to be affected by dehydration.   
This had led to elevated levels of some parameters, meaning that the 
analysis was of little value (Figure 3, Figure 4, Figure 5). The condi-
tions required for athlete blood passport (ABP) tests were not fulfilled 
either, as players were not required to rest for two hours post-match.   
Blood parameters are determined in a harmonised manner thanks 
to an external quality control programme for blood samples in which 
all WADA-accredited laboratories participate [25]. All laboratories 
use the same protocol and quality controls to ensure that results can 
be interpreted consistently and compared across laboratories. All 
blood parameters from samples collected in connection with UEFA 
EURO 2012 were sent to UEFA by the Warsaw laboratory to allow 
comparison with previous results. 
Growth hormone testing
Serum was tested for the presence of human growth hormone in both 
the out-of-competition and in-competition programmes (Table 6). 
All HGH tests were prepared using a special chemiluminescence 
immunoassay kit for HGH [26]. All results were expressed by 
means of two measured concentrations: the concentration result-
ing from the “REC” assay (corresponding roughly to the recombi-
nant HGH) and the concentration resulting from the “PIT” assay 
(corresponding to all HGH forms circulating in the blood).   
FIG. 1. DISTRIBUTION OF TESTOSTERONE TO EPITESTOSTERONE (T/E) 
RATIOS IN OUT-OF-COMPETITION SAMPLES AT UEFA EURO 2012
FIG. 4. CUMULATIVE FREQUENCY DISTRIBUTION OF RETICULOCYTE 
PERCENTAGES IN OUT-OF-COMPETITION SAMPLES AT UEFA EURO 2012
FIG. 3. CUMULATIVE FREQUENCY DISTRIBUTION OF HAEMOGLOBIN 
CONCENTRATION (G/L) IN OUT OF COMPETITION SAMPLES AT UEFA 
EURO 2012
FIG. 2. DISTRIBUTION OF TESTOSTERONE TO EPITESTOSTERONE (T/E) 
RATIOS IN IN-COMPETITION SAMPLES AT UEFA EURO 2012
FIG. 5. CUMULATIVE FREQUENCY DISTRIBUTION OF OFF SCORES IN 
OUT-OF-COMPETITION SAMPLES AT UEFA EURO 2012
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The ratio of the two concentrations was calculated in accordance 
with WADA guidelines [27]. Only negative samples were observed.
Non-steroidal anti-inflammatory drugs (NSAIDs)
NSAIDs were detected in a large number of samples, both in-
competition and out-of-competition. A relationship was found be-
tween the duration of the tournament and the number of samples 
containing NSAIDs. The most frequent compound was diclofenac, 
which was used more towards the end of the tournament.
Nicotine 
Very high concentrations of nicotine were observed in several 
samples. This high concentration is very rarely observed in routine 
anti-doping samples.
Declaration of medication
As is standard practice for doping controls, players were required 
to declare any medication that had recently been taken or admin-
istered prior to the control. Of the 124 players tested at the tourna-
ment, 65 (52%) declared that they had taken some sort of medi-
cine during the last three months, while 59 (48%) declared that 
they had not taken any medicine, or only vitamins or minerals.
Of the players who declared the recent use of medication, 4% 
declared that they had been given a local cortisone injection during 
the last three months and 54% (i.e. 35 of those 65) declared that 
they had taken (or were taking) NSAIDs. Thus, 28% of the players 
tested at the tournament had taken NSAIDS during the previous three 
months.
These findings suggest that treatment of musculoskeletal problems 
with local corticosteroids is uncommon in football, whereas treatment 
with NSAIDs is more frequent. However, the figure for NSAIDs is 
lower than at UEFA EURO 2008, where 44% of players tested re-
ported having taken NSAIDs. 
10% of the players tested declared that they had taken sleeping 
pills on account of insomnia during the last three months. 
Conclusion
The anti-doping programme conducted at UEFA EURO 2012 con-
tinued UEFA’s commitment to ensuring that the highest possible 
standards of doping deterrence and detection are applied at its 
major competitions. Following on from the process begun in 2008, 
all samples were analysed for the most advanced possible range 
of prohibited substances, using blood and urine samples processed 
at a laboratory accredited by WADA under the direction of some 
of the leading anti-doping laboratories in Europe. None of the 
samples collected returned positive results, although interesting 
levels of nicotine and NSAIDs (which are not prohibited) were 
detected during the tournament. The testing and analytical pro-
gramme employed is an excellent example of high quality co-ordi-
nated doping controls at a major team sport tournament.  
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OOC blood 
samples
IC blood 
samples
Total samples 160 120
REC PIT REC PIT
No. of samples above LOQ* 129 160 113 120
Percentage below LOQ 19% 0% 6% 0%
OOC samples 
above LOQ
IC samples 
above LOQ
No. of ratios 129 113
Mean of ratios 0.469 0.428
Median of ratios 0.432 0.423
SD**  0.182 0.133
Mean CV*** of ratios 39% 31%
Min. 0.178 0.855
Max. 0.182 1.133
WADA cut-off 1.81 1.81
TABLE 6. HGH RESULTS FOR BLOOD SAMPLES COLLECTED 
DURING TESTING
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